Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]

Vandetanib increases progression free survival in medullary thyroid carcinoma

Dr Nick Botwood - AstraZeneca, UK

Vandetanib increases progression free survival in medullary thyroid carcinoma ( Dr Nick Botwood - AstraZeneca, UK )

WINTHER: The WIN therapeutics clinical trial

Prof Josep Tabernero - Vall d'Hebron Institute of Oncology (VHIO), Barcelona...

WINTHER: The WIN therapeutics clinical trial ( Prof Josep Tabernero - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Best treatment for chronic lymphocytic leukaemia with 17p deletion

Prof Michael Keating - MD Anderson Cancer Center, Houston, USA

Best treatment for chronic lymphocytic leukaemia with 17p deletion ( Prof Michael Keating - MD Anderson Cancer Center, Houston, USA )

Use of genetic variance to identify potential therapeutic targets

Dr John Quackenbush - Dana-Farber Cancer Institute, Boston, USA

Use of genetic variance to identify potential therapeutic targets ( Dr John Quackenbush - Dana-Farber Cancer Institute, Boston, USA )

Introduction of PET tracers to the WINTHER trial

Robert Dann - Global Strategy Leader, Oncology/Pathology, GE Healthcare

Introduction of PET tracers to the WINTHER trial ( Robert Dann - Global Strategy Leader, Oncology/Pathology, GE Healthcare )

Next generation sequencing and WIN therapeutics

Dr Michael Pellini – Foundation Medicine, Cambridge, USA

Next generation sequencing and WIN therapeutics ( Dr Michael Pellini – Foundation Medicine, Cambridge, USA )

Shortening the timeline for clinical drug developments

Dr James Doroshow – National Cancer Institute, Bethesda, USA

Shortening the timeline for clinical drug developments ( Dr James Doroshow – National Cancer Institute, Bethesda, USA )

Building international collaborations and the WINTHER trial

Dr Oliver Bogler – MD Anderson Cancer Center, Houston, USA

Building international collaborations and the WINTHER trial ( Dr Oliver Bogler – MD Anderson Cancer Center, Houston, USA )

GFI is crucial for AML1-ETO induced acute myeloid leukemia

Dr Bert van der Reijden – Radboud University Nijmegen Medical Centre, Holland

GFI is crucial for AML1-ETO induced acute myeloid leukemia ( Dr Bert van der Reijden – Radboud University Nijmegen Medical Centre, Holland )

Signaling and targeting cellular pathways in leukaemia metabolism

Dr Jing Chen – Emory University School of Medicine, Atlanta, USA

Signaling and targeting cellular pathways in leukaemia metabolism ( Dr Jing Chen – Emory University School of Medicine, Atlanta, USA )

Use of mesenchymal stromal cells against graft-versus-host disease

Prof Willem Fibbe – Lieden University Medical Center, Holland

Use of mesenchymal stromal cells against graft-versus-host disease ( Prof Willem Fibbe – Lieden University Medical Center, Holland )

Next generation sequencing and the monoclonal structure of multiple myeloma

Dr Niccolo Bolli – University of Cambridge, UK

Next generation sequencing and the monoclonal structure of multiple myeloma ( Dr Niccolo Bolli – University of Cambridge, UK )

More from ecancer